Journal of Neural Transmission

, Volume 126, Issue 3, pp 309–318 | Cite as

Longterm outcome of cognition, affective state, and quality of life following subthalamic deep brain stimulation in Parkinson’s disease

  • Doreen GruberEmail author
  • Lisa Calmbach
  • Andrea A. Kühn
  • Patricia Krause
  • Ute A. Kopp
  • Gerd-Helge Schneider
  • Andreas Kupsch
Neurology and Preclinical Neurological Studies - Original Article


Normal cognition is an established selection criteria for subthalamic (STN) deep brain stimulation (DBS) in Parkinson’s disease (PD), while concern has been raised as to aggravated cognitive decline in PD patients following STN-DBS. The present longterm study investigates cognitive status in all patients (n = 104) suffering from PD, who were treated via continuous bilateral STN-DBS between 1997 and 2006 in a single institution. Preoperative neuropsychological results were available in 79/104 of the patients. Thirty-seven of these patients were additionally assessed after 6.3 ± 2.2 years (range 3.6–10.5 years) postsurgery via neuropsychological and motor test batteries, classifying cognitive conditions according to established criteria. At DBS-surgery patients, available for longterm follow-up (n = 37; mean age 67.6 ± 6.9 years, mean disease duration 11.3 ± 4.1 years), showed no (24.3%; 9/37) or mild preoperative cognitive impairment (MCI, 75.7%; 28/37). Postoperatively (mean disease duration: 17.1 ± 5.1 years), 19% of the patients (7/37) had no cognitive impairment, while 41% of the patients presented with either MCI or dementia (15/37, respectively). Preoperative MCI correlated with conversion to dementia by trend. Overall, STN-DBS-treated patients deteriorated by 1.6/140 points/year in the Mattis dementia rating scale. Disease duration, but not age, at DBS-surgery negatively correlated with postoperative cognitive decline and positively correlated with conversion to dementia. This observational, “real-life” study provides longterm results of cognitive decline in STN-DBS-treated patients with presurgical MCI possibly predicting the conversion to dementia. Although, the present data is lacking a control group of medically treated PD patients, comparison with other studies on cognition and PD do not support a disease-modifying effect of STN-DBS on cognitive domains.


Deep brain stimulation Parkinson’s disease Cognition Quality of life 



Beck Anxiety Inventory


Beck Depression Inventory


Brief Psychiatric Rating Scale


Bech-Rafaelsen-Mania Scale


Deep brain stimulation


Levodopa equivalent dosage


Montgomery and Asberg Depression Rating Scale


Modified Mattis Dementia Rating Scale


Multidimensional Mood State Questionnaire


Odds ratio


Parkinson’s disease


Parkinson’s disease with dementia


Parkinson’s disease with mild cognitive impairment


Parkinson’s disease with normal cognition

PDQ 39

Parkinson’s Disease Questionnaire


Quality of life


REM sleep behaviour disorder


Rey Auditory Verbal Learning Test

SF 36

36-item Short-Form Health Survey




Nucleus subthlamicus


Trail Making Test


Unified Parkinson’s Disease Rating Scale, motor subscore



We thank our patients for their continued support of our work.


University Medicine Berlin, Charité.

Compliance with ethical standards

Conflict of interest

DG has received honoraria for speaking from Medtronic, outside the submitted work. AAK is a consultant to Boston Scientific and has received honoraria for speaking from Medtronic, Boston Scientific and Abbott, also grants from Medtronic, all outside the submitted work. GHS has received honoraria for speaking from Medtronic, and Boston Scientific, outside the submitted work. AK has received honoraria for speaking from Medtronic and Abbott, outside the submitted work. LC and UK declare that they have no conflicts of interest.


  1. Aarsland D, Kurz MW (2010) The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 289(1–2):18–22. CrossRefGoogle Scholar
  2. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P (2001) Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 56(6):730–736CrossRefPubMedGoogle Scholar
  3. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60(3):387–392CrossRefGoogle Scholar
  4. Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 20(10):1255–1263. CrossRefPubMedGoogle Scholar
  5. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre M (2010) Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 75(12):1062–1069. CrossRefPubMedPubMedCentralGoogle Scholar
  6. Anang JB, Gagnon JF, Bertrand JA, Romenets SR, Latreille V, Panisset M, Montplaisir J, Postuma RB (2014) Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 83(14):1253–1260. CrossRefPubMedPubMedCentralGoogle Scholar
  7. Anang JB, Nomura T, Romenets SR, Nakashima K, Gagnon JF, Postuma RB (2017) Dementia predictors in parkinson disease: a validation study. J Parkinsons Dis 7(1):159–162. CrossRefPubMedGoogle Scholar
  8. Aybek S, Gronchi-Perrin A, Berney A, Chiuve SC, Villemure JG, Burkhard PR, Vingerhoets FJ (2007) Long-term cognitive profile and incidence of dementia after STN-DBS in Parkinson’s disease. Mov Disord 22(7):974–981. CrossRefPubMedGoogle Scholar
  9. Balzer-Geldsetzer M, Costa AS, Kronenburger M, Schulz JB, Roske S, Spottke A, Wullner U, Klockgether T, Storch A, Schneider C, Riedel O, Wittchen HU, Seifried C, Hilker R, Schmidt N, Witt K, Deuschl G, Mollenhauer B, Trenkwalder C, Liepelt-Scarfone I, Graber-Sultan S, Berg D, Gasser T, Kalbe E, Bodden M, Oertel WH, Dodel R (2011) Parkinson’s disease and dementia: a longitudinal study (DEMPARK). Neuroepidemiology 37(3–4):168–176. CrossRefPubMedGoogle Scholar
  10. Bech P, Bolwig TG, Kramp P, Rafaelsen OJ (1979) The Bech–Rafaelsen Mania Scale and the Hamilton Depression Scale. Acta Psychiatr Scand 59(4):420–430CrossRefPubMedGoogle Scholar
  11. Beck AT (1987) Beck Depression Inventory: manual. Psychological Corporation, San AntoniaGoogle Scholar
  12. Beck AT, Epstein N, Brown G, Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56(6):893–897CrossRefPubMedGoogle Scholar
  13. Bullinger M (1996) Assessment of health related quality of life with the SF-36 health survey. Rehabilitation (Stuttg) 35(3):XVII–XXVII (quiz XXVII–XXIX) Google Scholar
  14. Castrioto A, Lozano AM, Poon YY, Lang AE, Fallis M, Moro E (2011) Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 68(12):1550–1556. CrossRefGoogle Scholar
  15. Cereda E, Cilia R, Klersy C, Siri C, Pozzi B, Reali E, Colombo A, Zecchinelli AL, Mariani CB, Tesei S, Canesi M, Sacilotto G, Meucci N, Zini M, Isaias IU, Barichella M, Cassani E, Goldwurm S, Pezzoli G (2016) Dementia in Parkinson’s disease: is male gender a risk factor? Parkinsonism Relat Disord 26:67–72. CrossRefPubMedGoogle Scholar
  16. Coelho M, Ferreira JJ (2012) Late-stage Parkinson disease. Nat Rev Neurol 8(8):435–442. CrossRefPubMedGoogle Scholar
  17. Combs HL, Folley BS, Berry DT, Segerstrom SC, Han DY, Anderson-Mooney AJ, Walls BD, van Horne C (2015) Cognition and depression following deep brain stimulation of the subthalamic nucleus and globus pallidus pars internus in Parkinson’s disease: a meta-analysis. Neuropsychol Rev 25(4):439–454. CrossRefPubMedGoogle Scholar
  18. Daniels C, Krack P, Volkmann J, Pinsker MO, Krause M, Tronnier V, Kloss M, Schnitzler A, Wojtecki L, Botzel K, Danek A, Hilker R, Sturm V, Kupsch A, Karner E, Deuschl G, Witt K (2010) Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson’s disease. Mov Disord 25(11):1583–1589. CrossRefPubMedGoogle Scholar
  19. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, Daniels C, Deutschlander A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J (2006) A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 355(9):896–908CrossRefGoogle Scholar
  20. Domellof ME, Ekman U, Forsgren L, Elgh E (2015) Cognitive function in the early phase of Parkinson’s disease, a five-year follow-up. Acta Neurol Scand 132(2):79–88. CrossRefPubMedGoogle Scholar
  21. Eggert K, Oertel W, Reichmann H (2012) Parkinsonsyndrome-Diagnostik und Therapie. Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme Verlag, StuttgartGoogle Scholar
  22. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707. (quiz 1837) CrossRefGoogle Scholar
  23. Fahn S, Elton R, Members of the UPDRS Development Committee (1987) The unified parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in parkinson’s disease, vol 2. McMellam Health Care Information, Florham Park, pp 153–163Google Scholar
  24. Flemenbaum A, Zimmermann RL (1973) Inter- and intra-rater reliability of the Brief Psychiatric Rating Scale. Psychol Rep 32(3):783–792CrossRefPubMedGoogle Scholar
  25. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23(6):837–844. CrossRefGoogle Scholar
  26. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442CrossRefPubMedGoogle Scholar
  27. Kim HY (2014) Statistical notes for clinical researchers: nonparametric statistical methods: 2. Nonparametric methods for comparing three or more groups and repeated measures. Restor Dent Endod 39(4):329–332. CrossRefPubMedPubMedCentralGoogle Scholar
  28. Kim HJ, Jeon BS, Paek SH, Lee KM, Kim JY, Lee JY, Kim HJ, Yun JY, Kim YE, Yang HJ, Ehm G (2014) Long-term cognitive outcome of bilateral subthalamic deep brain stimulation in Parkinson’s disease. J Neurol. CrossRefPubMedGoogle Scholar
  29. Lezak M (1995) Neuropsychological assessment. Oxford University Press, New YorkGoogle Scholar
  30. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Mov Disord 27(3):349–356. CrossRefPubMedPubMedCentralGoogle Scholar
  31. Marder K, Tang MX, Cote L, Stern Y, Mayeux R (1995) The frequency and associated risk factors for dementia in patients with Parkinson’s disease. Arch Neurol 52(7):695–701CrossRefPubMedGoogle Scholar
  32. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, Group NV (2011) The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord 26(3):399–406. CrossRefGoogle Scholar
  33. Mattis S (1988) Dementia Rating Scale: professional manual. Psychological Assessment Resources, OdessaGoogle Scholar
  34. Merola A, Zibetti M, Angrisano S, Rizzi L, Ricchi V, Artusi CA, Lanotte M, Rizzone MG, Lopiano L (2011) Parkinson’s disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. Brain 134(Pt 7):2074–2084. CrossRefGoogle Scholar
  35. Merola A, Rizzi L, Artusi CA, Zibetti M, Rizzone MG, Romagnolo A, Bernardini A, Lanotte M, Lopiano L (2014) Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients. J Neurol 261(9):1745–1751. CrossRefPubMedGoogle Scholar
  36. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389CrossRefGoogle Scholar
  37. Odekerken VJ, Boel JA, Schmand BA, de Haan RJ, Figee M, van den Munckhof P, Schuurman PR, de Bie RM, Group Ns (2016) GPi vs STN deep brain stimulation for Parkinson disease: three-year follow-up. Neurology 86(8):755–761. CrossRefPubMedGoogle Scholar
  38. Pedersen KF, Larsen JP, Tysnes OB, Alves G (2017) Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study. Neurology 88(8):767–774. CrossRefPubMedGoogle Scholar
  39. Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destee A, Meissner WG, Tison F, Rascol O, of the CSG (2017) L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. Eur J Neurol. CrossRefPubMedGoogle Scholar
  40. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 4(3):241–248CrossRefPubMedGoogle Scholar
  41. Pigott K, Rick J, Xie SX, Hurtig H, Chen-Plotkin A, Duda JE, Morley JF, Chahine LM, Dahodwala N, Akhtar RS, Siderowf A, Trojanowski JQ, Weintraub D (2015) Longitudinal study of normal cognition in Parkinson disease. Neurology 85(15):1276–1282. CrossRefPubMedPubMedCentralGoogle Scholar
  42. Rahman S, Griffin HJ, Quinn NP, Jahanshahi M (2008) Quality of life in Parkinson’s disease: the relative importance of the symptoms. Mov Disord 23(10):1428–1434. CrossRefPubMedGoogle Scholar
  43. Rizzone MG, Fasano A, Daniele A, Zibetti M, Merola A, Rizzi L, Piano C, Piccininni C, Romito LM, Lopiano L, Albanese A (2014) Long-term outcome of subthalamic nucleus DBS in Parkinson’s disease: from the advanced phase towards the late stage of the disease?. Parkinsonism Relat Disord. CrossRefPubMedGoogle Scholar
  44. Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 69(3):308–312CrossRefPubMedPubMedCentralGoogle Scholar
  45. Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Halbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider GH, Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto JL, Bataille B, Maltete D, Damier P, Raoul S, Sixel-Doering F, Hellwig D, Gharabaghi A, Kruger R, Pinsker MO, Amtage F, Regis JM, Witjas T, Thobois S, Mertens P, Kloss M, Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, Schade-Brittinger C, Deuschl G (2013) Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med 368(7):610–622. CrossRefGoogle Scholar
  46. Smeding HM, Speelman JD, Koning-Haanstra M, Schuurman PR, Nijssen P, van Laar T, Schmand B (2006) Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology 66(12):1830–1836. CrossRefPubMedGoogle Scholar
  47. Smeding HM, Speelman JD, Huizenga HM, Schuurman PR, Schmand B (2011) Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson’s disease. J Neurol Neurosurg Psychiatry 82(7):754–760. CrossRefPubMedGoogle Scholar
  48. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P (1995) A scale for the assessment of hedonic tone the Snaith–Hamilton Pleasure Scale. Br J Psychiatry 167(1):99–103CrossRefGoogle Scholar
  49. Steyer R, Schwenkmezger P, Notz P, Eid M (1997) Der Mehrdimensionale Befindlichkeitsfragebogen (MDBF). Hogrefe, GöttingenGoogle Scholar
  50. Volkmann J, Daniels C, Witt K (2010) Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat Rev Neurol 6(9):487–498. CrossRefPubMedGoogle Scholar
  51. Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, Rothlind J, Sagher O, Reda D, Moy CS, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein J, Stoner G, Heemskerk J, Huang GD, Group CSPS (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301(1):63–73. CrossRefPubMedPubMedCentralGoogle Scholar
  52. Williams A, Gill S, Varma T, Jenkinson C, Quinn N, Mitchell R, Scott R, Ives N, Rick C, Daniels J, Patel S, Wheatley K, Group PSC (2010) Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 9(6):581–591. CrossRefPubMedPubMedCentralGoogle Scholar
  53. Witt K, Daniels C, Reiff J, Krack P, Volkmann J, Pinsker MO, Krause M, Tronnier V, Kloss M, Schnitzler A, Wojtecki L, Botzel K, Danek A, Hilker R, Sturm V, Kupsch A, Karner E, Deuschl G (2008) Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study. Lancet Neurol 7(7):605–614. CrossRefPubMedGoogle Scholar
  54. York MK, Dulay M, Macias A, Levin HS, Grossman R, Simpson R, Jankovic J (2008) Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 79(7):789–795. CrossRefPubMedGoogle Scholar
  55. Zangaglia R, Pacchetti C, Pasotti C, Mancini F, Servello D, Sinforiani E, Cristina S, Sassi M, Nappi G (2009) Deep brain stimulation and cognitive functions in Parkinson’s disease: a three-year controlled study. Mov Disord 24(11):1621–1628. CrossRefPubMedGoogle Scholar
  56. Zangaglia R, Pasotti C, Mancini F, Servello D, Sinforiani E, Pacchetti C (2012) Deep brain stimulation and cognition in Parkinson’s disease: an eight-year follow-up study. Mov Disord 27(9):1192–1194. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  • Doreen Gruber
    • 1
    • 2
    • 4
    Email author
  • Lisa Calmbach
    • 2
    • 4
  • Andrea A. Kühn
    • 2
  • Patricia Krause
    • 2
  • Ute A. Kopp
    • 2
  • Gerd-Helge Schneider
    • 3
  • Andreas Kupsch
    • 4
    • 5
  1. 1.Movement Disorders ClinicBeelitz-HeilstaettenGermany
  2. 2.Movement Disorders and Neuromodulation Unit, Department of NeurologyCharité University Medicine BerlinBerlinGermany
  3. 3.Department of NeurosurgeryCharité University Medicine BerlinBerlinGermany
  4. 4.Department of Neurology and Stereotactic NeurosurgeryOtto-von-Guericke-UniversityMagdeburgGermany
  5. 5.NEUROLOGY MOVES, Movement Disorder Center BerlinBerlinGermany

Personalised recommendations